Dividendos de Cassava Sciences
Dividendo controles de criterios 0/6
Cassava Sciences does not have a record of paying a dividend.
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
Rentabilidad media de la industria | 2.3% |
Próxima fecha de pago de dividendos | n/a |
Fecha ex dividendo | n/a |
Dividendo por acción | n/a |
Beneficios por acción | -US$2.25 |
Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
No hay actualizaciones
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if SAVA's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if SAVA's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
Rentabilidad por dividendo de Cassava Sciences vs. Mercado |
---|
Segmento | Rentabilidad por dividendo |
---|---|
Empresa (SAVA) | n/a |
Suelo de mercado 25% (US) | 1.5% |
Techo de mercado 25% (US) | 4.7% |
Media de la industria (Pharmaceuticals) | 2.3% |
Previsión de analistas en 3 años (SAVA) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de SAVA en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de SAVA en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de SAVA para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as SAVA has not reported any payouts.